Table 2.
Ref. | Year |
1-yr survival |
2-yr survival |
3-yr survival |
|||
TACE + 3D-CRT | TACE alone | TACE + 3D-CRT | TACE alone | TACE + 3D-CRT | TACE alone | ||
Chia-Hsien Cheng et al[25] | 2001 | 58.0% | 56.0% | ||||
Lan et al[24] | 2005 | 57.1% | 61.7% | 40.5% | 30.0% | 26.2% | 16.7% |
Li et al[23] | 2003 | 73.2% | 54.8% | 58.7% | 27.3% | 41.9% | 12.8% |
Liao et al[22] | 2010 | 74.0% | 50.0% | 30.0% | 14.0% | ||
Liu et al[21] | 2005 | 66.5% | 53.9% | 48.4% | 37.2% | 37.4% | 17.8% |
Shang et al[20] | 2007 | 78.0% | 50.0% | 60.0% | 32.0% | 34.0% | 18.0% |
Shim et al[19] | 2005 | 36.8% | 14.3% | ||||
Wu et al[18] | 2004 | 90.2% | 89.7% | 75.6% | 58.7% | 44.6% | 24.0% |
Zeng et al[17] | 2004 | 71.5% | 59.6% | 42.3% | 26.5% | 24.0% | 11.1% |
Zhao et al[16] | 2006 | 82.0% | 55.0% | 63.0% | 28.0% | 43.0% | 15.0% |
TACE: Transcatheter arterial chemoembolization; 3D-CRT: Three-dimensional conformal radiotherapy.